$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
A comprehensive comparison of the efficacy and side effects of furmonertinib and osimertinib
2026-02-01 22:25:32
Check Details
Ensifentrine-Ohtuvayre market price in 2025 and possibility of inclusion in medical insurance
2026-02-01 22:25:32
Check Details
How long does it take to take Roaccutane (isotretinoin) soft capsules to see significant improvement?
2026-02-01 22:25:32
Check Details
Whether Doxorubicin has been included in the medical insurance catalog in 2025 and patient purchasing guide
2026-02-01 22:25:32
Check Details
What are the indications for Everolimus (Afinitor)? Which patients are suitable for this drug?
2026-02-01 22:25:32
Check Details
Evaluation of the efficacy and clinical effectiveness of estramustine (Adelax) in the treatment of prostate cancer
2026-02-01 22:25:32
Check Details
Common side effects of seripalase (BRINEURA) and instructions on how patients should deal with and prevent them
2026-02-01 22:25:32
Check Details
What is Eslicarbazepine? Its pharmacological classification and therapeutic characteristics
2026-02-01 22:25:32
Check Details
How is Anagrelide clinically effective and patients’ real medication experience shared
2026-02-01 22:25:32
Check Details
Standard dosage and usage of apalutamide (Ansenko) and suggestions for individualized medication adjustment
2026-02-01 22:25:32
Check Details
Is elacestrant a chemotherapy drug or a targeted drug? Description of its pharmacological mechanism of action
2026-02-01 22:25:32
Check Details
Differences and selection suggestions between F/TAF and Bituvi in u200bu200bterms of efficacy and applicable groups
2026-02-01 22:25:32
Check Details
1
2
...
2170
2171
2172
2173
2174
2175
2176
...
10240
10241
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring
2
Pirtobrutinib and Risks of Atrial Fibrillation and Bleeding: Mechanism, Data Interpretation and Monitoring
3
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
4
Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen
5
Ponatinib in the PACE Phase II Trial: Response Data in Resistant CML and Ph+ ALL
6
Selumetinib for NF1-Related Plexiform Neurofibromas: Time to Response and Response Assessment
7
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
8
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
9
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
10
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
11
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
12
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks